RxDoctor Payments Data

Weiguo Li, MD

Family Medicine · King Of Prussia, PANPI 1295931038

Payments from drug & device makers

$3,127in general payments, 2019–2025

Across 116 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$897
  • Novartis$473
  • Amgen$284
  • Abbott$260
  • Qiagen, LLC$226
  • AbbVie$190
  • plus $796 from 12 others

What the payments were for

  • Food & beverage$3,09999%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,127 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,831
Medicare patients
73
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$19,457
Breo ElliptaFluticasone/Vilanterol21$8,484
Atorvastatin Calcium175$1,925
Losartan Potassium60$1,054
Rosuvastatin Calcium51$862
Valsartan22$843
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide25$826
Tamsulosin Hcl46$656
Lisinopril68$565
Metformin Hcl69$555
Mirtazapine12$425
Metoprolol Succinate24$422
Amlodipine Besylate62$405
Metformin Hcl ErMetformin Hcl20$403
FenofibrateFenofibrate Nanocrystallized14$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$97$8,48421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in King Of Prussia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →